ImmunityBio Reports 94% Revenue Growth to $51.2 Million in Q2 2026

ImmunityBio, Inc. reported significant financial results for the second quarter of 2026, with total revenue reaching $51.2 million, a 94% increase compared to $26.4 million in the same period last year. The company's product revenue, primarily from its immunotherapy ANKTIVA, surged by 92% year-over-year to $50.7 million, reflecting strong market adoption and continued sales growth. For the first half of 2026, total revenue was $95.4 million, up 122% from $42.9 million in the first half of 2025. Despite this revenue growth, the company reported a net loss of $230.4 million for the quarter, compared to a loss of $92.6 million in the prior year, largely due to increased operating expenses and significant changes in the fair value of related-party convertible notes and warrant liabilities.

Operating expenses for the second quarter totaled $112.9 million, a 16% increase from $97.7 million in the same quarter of 2025. Research and development expenses rose by 10% to $60.8 million, driven by higher clinical trial costs and personnel-related expenses. Selling, general, and administrative expenses also increased by 22% to $51.8 million, reflecting costs associated with commercialization efforts and professional services. The company’s total liabilities as of June 30, 2026, stood at $1.67 billion, up from $1.00 billion at the end of 2025, primarily due to an increase in related-party convertible notes and revenue interest liabilities.

Strategically, ImmunityBio has made significant advancements, including the acceptance of a supplemental Biologics License Application (sBLA) for ANKTIVA by the FDA, with a target action date set for January 6, 2027. The company also received broad marketing authorization for ANKTIVA from the Emirates Drug Establishment (EDE) in the UAE, covering multiple indications. Additionally, ImmunityBio entered into a development and supply agreement with Japan BCG Laboratory (JBL) to secure exclusive U.S. rights for the Tokyo-172 BCG, enhancing its supply chain for bladder cancer treatments.

As of June 30, 2026, ImmunityBio had cash and cash equivalents, along with marketable securities, totaling $357.4 million, an increase from $242.8 million at the end of 2025. The company anticipates needing additional financing to support ongoing operations and the commercialization of ANKTIVA, as well as to fund the development of its pipeline candidates. The management expressed confidence in its ability to secure necessary funding through equity offerings and potential loans from affiliated entities, although they acknowledged the inherent risks and uncertainties in achieving these financial goals.